What is the most recent earnings date for NAUT stock?
NAUTILUS BIOTECHNOLOGY INC (NAUT) last reported earnings on 2/26/2026.
NASDAQ:NAUT • US63909J1088
Past quarterly earnings results for NAUTILUS BIOTECHNOLOGY INC (NAUT), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.11 | -0.14 | 22.97% | 21.43% | - | - | ||
| Q3 2025 | -0.11 | -0.15 | 28.10% | 15.38% | - | - | ||
| Q2 2025 | -0.12 | -0.16 | 24.10% | 14.29% | - | - | ||
| Q1 2025 | -0.13 | -0.15 | 13.06% | 13.33% | - | - | ||
| Q4 2024 | -0.14 | -0.17 | 15.27% | - | - | - | ||
| Q3 2024 | -0.13 | -0.17 | 22.76% | - | - | - | ||
| Q2 2024 | -0.14 | -0.17 | 16.31% | -7.69% | - | - | ||
| Q1 2024 | -0.15 | -0.17 | 9.50% | -25.00% | - | - | ||
| Q4 2023 | -0.14 | -0.15 | 5.34% | -27.27% | - | - | ||
| Q3 2023 | -0.13 | -0.17 | 23.91% | -18.18% | - | - | ||
| Q2 2023 | -0.13 | -0.15 | 15.03% | -8.33% | - | - | ||
| Q1 2023 | -0.12 | -0.17 | 29.41% | 7.69% | - | - | ||
| Q4 2022 | -0.11 | -0.16 | 29.67% | 15.38% | - | - | ||
| Q3 2022 | -0.11 | -0.15 | 26.89% | 8.33% | - | - | ||
| Q2 2022 | -0.12 | -0.17 | 29.76% | 36.84% | - | - | ||
| Q1 2022 | -0.13 | -0.16 | 18.65% | - | 255K | -100.00% | - | |
| Q4 2021 | -0.13 | -0.14 | 3.81% | - | - | - | ||
| Q3 2021 | -0.12 | -0.10 | -17.65% | - | - | - | ||
| Q2 2021 | -0.19 | -0.07 | -166.11% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
NAUTILUS BIOTECHNOLOGY INC (NAUT) last reported earnings on 2/26/2026.
NAUTILUS BIOTECHNOLOGY INC (NAUT) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, NAUTILUS BIOTECHNOLOGY INC (NAUT) has beaten EPS estimates in 4 out of 4 releases.